Characterization of two novel tritiated radioligands for labelling Neuropeptide FF (NPFF1 and NPFF2) receptors

Neurochemistry International

Volumn 55, Issue 8, 2009, Pages 815-819

  Talmont, Franck ^a,b   Garcia, Laura Piedra ^a,b   Mazarguil, Honoré ^a,b   Zajac, Jean Marie ^a,b   Mollereau, Catherine ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Binding; Neuropeptide FF; Radioligand; Receptor

Indexed keywords

NEUROPEPTIDE FF1 RECEPTOR; NEUROPEPTIDE FF2 RECEPTOR; NEUROPEPTIDE RECEPTOR; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; CHO CELL; CONTROLLED STUDY; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; CROSS REACTIONS; EYE PROTEINS; HUMANS; KINETICS; LIGANDS; NEUROPEPTIDES; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, NEUROPEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TIME FACTORS; TRITIUM;

EID: 70349968027     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.08.004     Document Type: Article

References (36)

1. Allard M., Geoffre S., Legendre P., Vincent J.D., and Simonnet G. Characterization of rat spinal cord receptors to FLFQPQRFamide, a mammalian morphine modulating peptide: a binding study. Brain Res. 500 1-2 (1989) 169-176
2. Bonini J.A., Jones K.A., Adham N., Forray C., Artymyshyn R., Durkin M.M., Smith K.E., Tamm J.A., Boteju L.W., Lakhlani P.P., Raddatz R., Yao W.J., Ogozalek K.L., Boyle N., Kouranova E.V., Quan Y., Vaysse P.J., Wetzel J.M., Branchek T.A., Gerald C., and Borowsky B. Identification and characterization of two G protein-coupled receptors for Neuropeptide FF. J. Biol. Chem. 275 50 (2000) 39324-39331
3. Desprat C., and Zajac J.M. Ontogeny of neuropeptide FF pharmacology and receptors in mouse brain. Brain Res. Dev. Brain Res. 82 1-2 (1994) 118-126
4. Devillers J.P., Mazarguil H., Allard M., Dickenson A.H., Zajac J.M., and Simonnet G. Characterization of a potent agonist for NPFF receptors: binding study on rat spinal cord membranes. Neuropharmacology 33 5 (1994) 661-669
5. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., and Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 48 4 (1996) 567-592
6. Dooley C.T., and Houghten R.A. Orphanin FQ/nociceptin receptor binding studies. Peptides 21 7 (2000) 949-960
7. Dupouy V., and Zajac J.M. Neuropeptide FF receptors in rat brain: a quantitative light-microscopic autoradiographic study using [125I][D.Tyr1, (NMe)Phe3]NPFF. Synapse 24 3 (1996) 282-296
8. Elshourbagy N.A., Ames R.S., Fitzgerald L.R., Foley J.J., Chambers J.K., Szekeres P.G., Evans N.A., Schmidt D.B., Buckley P.T., Dytko G.M., Murdock P.R., Milligan G., Groarke D.A., Tan K.B., Shabon U., Nuthulaganti P., Wang D.Y., Wilson S., Bergsma D.J., and Sarau H.M. Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor. J. Biol. Chem. 275 34 (2000) 25965-25971
9. Gicquel S., Mazarguil H., Desprat C., Allard M., Devillers J.P., Simonnet G., and Zajac J.M. Structure-activity study of neuropeptide FF: contribution of N-terminal regions to affinity and activity. J. Med. Chem. 37 21 (1994) 3477-3481
10. Gouarderes C., Mollereau C., Tafani J.A., Mazarguil H., and Zajac J. [(125)I]EYF: a new high affinity radioligand to neuropeptide FF receptors. Peptides 22 4 (2001) 623-629
11. Gouarderes C., Quelven I., Mollereau C., Mazarguil H., Rice S.Q., and Zajac J.M. Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands. Neuroscience 115 2 (2002) 349-361
12. Gouarderes C., Tafani J.A., Mazarguil H., and Zajac J.M. Autoradiographic characterization of rat spinal neuropeptide FF receptors by using [125I][D.Tyr1, (NMe)Phe3]NPFF. Brain Res. Bull. 42 3 (1997) 231-238
13. Hinuma S., Shintani Y., Fukusumi S., Iijima N., Matsumoto Y., Hosoya M., Fujii R., Watanabe T., Kikuchi K., Terao Y., Yano T., Yamamoto T., Kawamata Y., Habata Y., Asada M., Kitada C., Kurokawa T., Onda H., Nishimura O., Tanaka M., Ibata Y., and Fujino M. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat. Cell Biol. 2 10 (2000) 703-708
14. Hjorth S.A., Thirstrup K., and Schwartz T.W. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor. Mol. Pharmacol. 50 4 (1996) 977-984
15. Kersante F., Mollereau C., Zajac J.M., and Roumy M. Anti-opioid activities of NPFF(1) receptors in a SH-SY5Y model. Peptides 27 5 (2006) 980-989
16. Liu Q., Guan X.M., Martin W.J., McDonald T.P., Clements M.K., Jiang Q., Zeng Z., Jacobson M., Williams Jr. D.L., Yu H., Bomford D., Figueroa D., Mallee J., Wang R., Evans J., Gould R., and Austin C.P. Identification and characterization of novel mammalian neuropeptide ff-like peptides that attenuate morphine-induced antinociception. J. Biol. Chem. 276 40 (2001) 36961-36969
17. Manik C.P., Molinoff P.B., and McGonigle P. Comparison of 125I-SCH 23982 and [3H]SCH 23390 as ligands for the D-1 dopamine receptor. J. Neurochem. 51 2 (1988) 391-397
18. Mollereau C., Gouarderes C., Dumont Y., Kotani M., Detheux M., Doods H., Parmentier M., Quirion R., and Zajac J.M. Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226. Br. J. Pharmacol. 133 1 (2001) 1-4
19. Mollereau C., Mazarguil H., Marcus D., Quelven I., Kotani M., Lannoy V., Dumont Y., Quirion R., Detheux M., Parmentier M., and Zajac J.M. Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists. Eur. J. Pharmacol. 451 3 (2002) 245-256
20. Mollereau C., Mazarguil H., Zajac J.M., and Roumy M. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol. Pharmacol. 67 3 (2005) 965-975
21. Mollereau C., Roumy M., and Zajac J.M. Opioid-modulating peptides: mechanisms of action. Curr. Top. Med. Chem. 5 3 (2005) 341-355
22. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Seroogy K.B., Hamon M., and Roques B.P. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol. Rev. 51 4 (1999) 745-781
23. Panula P., Kalso E., Nieminen M., Kontinen V.K., Brandt A., and Pertovaara A. Neuropeptide FF and modulation of pain. Brain Res. 848 1-2 (1999) 191-196
24. Perry S.J., Yi-Kung Huang E., Cronk D., Bagust J., Sharma R., Walker R.J., Wilson S., and Burke J.F. A human gene encoding morphine modulating peptides related to NPFF and FMRFamide. FEBS Lett. 409 3 (1997) 426-430
25. Rosenkilde M.M., Cahir M., Gether U., Hjorth S.A., and Schwartz T.W. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J. Biol. Chem. 269 45 (1994) 28160-28164
26. Rothman R.B. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 12 2 (1992) 129-138
27. Roumy M., Lorenzo C., Mazeres S., Bouchet S., Zajac J.M., and Mollereau C. Physical association between neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activity. J. Biol. Chem. 282 11 (2007) 8332-8342
28. Roumy M., and Zajac J.M. Neuropeptide FF, pain and analgesia. Eur. J. Pharmacol. 345 1 (1998) 1-11
29. Siehler S., Seuwen K., and Hoyer D. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur. J. Pharmacol. 348 2-3 (1998) 311-320
30. Simonin F., Schmitt M., Laulin J.P., Laboureyras E., Jhamandas J.H., MacTavish D., Matifas A., Mollereau C., Laurent P., Parmentier M., Kieffer B.L., Bourguignon J.J., and Simonnet G. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc. Natl. Acad. Sci. U S A 103 2 (2006) 466-471
31. Vilim F.S., Aarnisalo A.A., Nieminen M.L., Lintunen M., Karlstedt K., Kontinen V.K., Kalso E., States B., Panula P., and Ziff E. Gene for pain modulatory neuropeptide NPFF: induction in spinal cord by noxious stimuli. Mol. Pharmacol. 55 5 (1999) 804-811
32. Vyas N., Mollereau C., Cheve G., and McCurdy C.R. Structure-activity relationships of neuropeptide FF and related peptidic and non-peptidic derivatives. Peptides 27 5 (2006) 990-996
33. Yang H.Y., Fratta W., Majane E.A., and Costa E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc. Natl. Acad. Sci. U S A 82 22 (1985) 7757-7761
34. Yang H.Y., Tao T., and Iadarola M.J. Modulatory role of neuropeptide FF system in nociception and opiate analgesia. Neuropeptides 42 1 (2008) 1-18
35. Zajac J.M. Neuropeptide FF: new molecular insights. Trends Pharmacol. Sci. 22 2 (2001) 63
36. Zajac J.-M., and Roques B.P. Properties required for reversible and irreversible radiolabelled probes for selective characterization of brain receptors and peptidases by autoradiography. In: Shariff N.A., and Lewis M.E. (Eds). Brain Imaging: Techniques and Application (1989), Ellis Horwood, Chichester pp. 18-35